Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.

MLA

Mariotti, Melinda, et al. “Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.” Pharmaceutics, vol. 16, no. 9, Sept. 2024, p. 1218. EBSCOhost, https://doi.org/10.3390/pharmaceutics16091218.

APA

Mariotti, M., Giacon, N., Lo Cascio, E., Cacaci, M., Picchietti, S., Di Vito, M., Sanguinetti, M., Arcovito, A., & Bugli, F. (2024). Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy. Pharmaceutics, 16(9), 1218. https://doi.org/10.3390/pharmaceutics16091218

Chicago

Mariotti, Melinda, Noah Giacon, Ettore Lo Cascio, Margherita Cacaci, Simona Picchietti, Maura Di Vito, Maurizio Sanguinetti, Alessandro Arcovito, and Francesca Bugli. 2024. “Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.” Pharmaceutics 16 (9): 1218. doi:10.3390/pharmaceutics16091218.